JNJ Novinky na Forexe
Johnson & Johnson Q3 Profit Plunges, Lifts FY26 Outlook; Stock Drops
Drug major Johnson & Johnson on Tuesday reported sharply lower third-quarter profit on special charges, despite sales growth. Further, the firm raised its fiscal 2026 outlook again and announced a quarterly dividend. In pre-market activity, the shares were losing around 2.6 percent.
RTTNews
|
Pred 18 dňami
Johnson & Johnson Lifts FY26 View, Despite Nearly Flat Q2 Profit; Stock Down
Drug major Johnson & Johnson, while reporting slightly lower second-quarter profit despite sales growth, on Wednesday raised again its earnings and sales forecast for fiscal 2026. The company also announced a quarterly dividend. In pre-market activity, the shares were losing around 1.9 percent.
RTTNews
|
Pred 108 dňami
Johnson & Johnson Q1 Profit Down, Sales Rise; Lifts FY26 Outlook
Drug major Johnson & Johnson (JNJ), while reporting sharply lower first-quarter profit despite sales growth, on Tuesday lifted fiscal 2026 earnings and sales forecast for fiscal 2026. The company also announced higher quarterly dividend. In pre-market activity, the shares were losing around 1.6 percent.
RTTNews
|
Pred 200 dňami
Johnson & Johnson In Deal With Trump Administration To Cut Drug Prices, Get Tariff Exemption
Drug major Johnson & Johnson has announced an agreement with the Trump Administration to lower drug prices, enabling millions of Americans to access medicines at significantly discounted rates. As part of the deal, the company's pharmaceutical products will be exempt from tariffs, though the specific terms remain confidential.
RTTNews
|
Pred 296 dňami
Johnson & Johnson Q2 Adj. EPS Beats View, Cuts FY24 Earnings Forecast
Johnson & Johnson reported Wednesday weak profit in its second quarter on charges, while adjusted earnings beat market estimates on sales growth. The drug major further trimmed its fiscal 2024 adjusted earnings outlook, but lifted operational sales view to mainly reflect the acquisition of Shockwave Medical. In pre-market activity on the NYSE, Johnson & Johnson shares were losing around 0.5...
RTTNews
|
Pred 836 dňami
Johnson & Johnson To Acquire Rights To Numab Therapeutics' Clinical-Stage Bispecific Antibody NM26
Johnson & Johnson (JNJ) announced Tuesday it has entered into a definitive agreement with biotechnology company Numab Therapeutics to acquire its wholly-owned subsidiary from Numab's shareholders in an all-cash transaction of approximately $1.25 billion.
RTTNews
|
Pred 886 dňami
J&J Seeks EMA Approval For DARZALEX Quadruplet Therapy For Multiple Myeloma
Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), announced Wednesday the submission of a Type II variation application to the European Medicines Agency (EMA).
RTTNews
|
Pred 969 dňami
AC Immune Advances Anti-pTau Active Immunotherapy For Alzheimer's Disease Into Phase 2b Trial
Swiss biopharmaceutical company AC Immune SA (ACIU) announced Friday that its development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical Alzheimer's disease (AD), those individuals not yet showing symptoms.
RTTNews
|
Pred 1051 dňami
Integra LifeSciences To Acquire Acclarent For $275 Mln Cash
Medical technology firm Integra LifeSciences Holdings Corp. (IART) announced Wednesday that it has entered into a definitive agreement to acquire Acclarent, Inc. from Ethicon, Inc., a Johnson & Johnson MedTech company, for $275 million in cash at closing. This is subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones.
RTTNews
|
Pred 1054 dňami
Johnson & Johnson Guides FY24 Adj. EPS Below Estimates
Ahead of the meeting with the investment community at the New York Stock Exchange later on Tuesday, Johnson & Johnson (JNJ) initiated financial guidance for the full-year 2024 and for the long term.
RTTNews
|
Pred 1061 dňami
